"Trikafta," an innovative and high-cost medication for treating the progressive genetic disease cystic fibrosis, has arrived in Georgia

Distribution of the drug to eligible beneficiaries will begin in the coming days.

According to the Ministry of Health of Georgia, the inclusion of "Trikafta" in the state program creates new treatment opportunities for individuals with cystic fibrosis. The drug extends life expectancy and significantly improves quality of life. It acts directly on the genetic mechanism underlying the disease, improves lung function, and reduces the risk of exacerbations and hospitalizations.

Patients have already begun the necessary medical examinations prior to starting treatment. Assessments of the beneficiaries' health status and their readiness to commence treatment are currently underway. This process facilitates the safe initiation of treatment and the planning of subsequent medical monitoring.

Cystic fibrosis is a progressive genetic disease that primarily affects the lungs and the digestive system. It is often accompanied by recurrent respiratory infections and can lead to a significant decline in lung function over time. The need for ongoing treatment and the limitations imposed by the disease impact an individual's daily life and quality of life; therefore, access to modern therapy is of particular importance.

The Minister of Health personally informed individuals with cystic fibrosis and their families about the agreement with the manufacturer one month ago.

The medication is intended for individuals aged two years and older whose genetic mutations align with the indications approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Approximately 110 people are registered with a diagnosis of cystic fibrosis in Georgia; of these, around 60 carry the relevant genetic mutations.

The Ministry of Health has worked consistently to increase access to modern treatments through active collaboration with the medical community, individuals living with cystic fibrosis, and their families. To this end, the Ministry has progressively expanded the range of services and medications covered by the state program. In 2025, inhaled medications, antibiotics, vitamins, and other drugs were added to the program, and funding for inpatient services was increased.